Tertomotide Uses, Dosage, Side Effects and more
Tertomotide is under investigation in clinical trial NCT01223209 (A Study, Combination, Immunologic Study of LTX-315 as adjunct to tertomotide in Patients Following Curative Surgery for Carcinoma). It is a peptide vaccine that activates the immune system so that it recognizes and kills cancer cells. It is being developed by Pharmexa A/S.
Tertomotide is a peptide vaccine that activates the immune system so that it recognises and kills cancer cells.
| Trade Name | Tertomotide |
| Generic | Tertomotide |
| Tertomotide Other Names | Tertomotide |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How Tertomotide works
Tertomotide targets an enzyme called telomerase. Telomerase is seldom found in normal cell types but is overexpressed in most cancer cells.
